Summary
A randomized controlled study comparing once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers was carried out in 99 Japanese patients. Endoscopic examinations were performed at the baseline and repeated at 3-week intervals until healing was confirmed. Eighty-two patients fulfilled the evaluation criteria (38 in the morning group and 44 in the bedtime group). In 13 of these patients the antisecretory effects of these regimens were also assessed by 24 h intragastric pH monitoring. The healing rates were 66% after 3 weeks and 95% after 6 weeks in the morning group, and 57% after 3 weeks and 80% after 6 weeks in the bedtime group. The differences were insignificant between the two groups, but there was a higher healing rate tendency after 6 weeks in the morning group (0.05<P<0.10). Regarding pain subsidence, there were no significant differences between the two groups. Both treatments were significantly superior to the controlgroup in increasing 24 h intragastric pH. The morning regimen was significantly superior to the bedtime regimen in suppression of daytime acidity. On the contrary, the bedtime regimen was significantly superior to the morning regimen in suppression of nocturnal acidity. These findings suggest that suppression of nocturnal acidity is important but not essential to promote duodenal ulcer healing and suppression of daytime acidity is equally important. Thus, once-a-day morning administration of 40 mg famotidine seems to be at least as effective as once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gledhill T, Howard OM, Buck M: Single nocturnal dose of an H2-receptor antagonist for the treatment of duodenal ulcers. Gut 1983;24:904–908.
Granata F: Comparison between ranitidine 150 mg bd and ranitidine 300 mg at bedtime in the management of duodenal ulcers. Ital J Gastroenterol 1985;17:208–210.
Ireland A, Colin-Jones DG, Gear P, et al: Ranitidine 150 mg twice daily as 300 mg nightly in the treatment of duodenal ulcers. Lancet 1984;2:274–276.
Farley A, Levesque D, Pare P, et al: A comparative trial of ranitidine 300 mg at night with ranitidine 150 mg twice daily in the treatment of duodenal and gastric ulcers. Am J Gastroenterol 1985;80:665–668.
Bianchi Porro G, Dicenta C, Cood J, et al: Review of an extensive worldwide study of new H2-receptor antagonist, famotidine, as compared to ranitidine in the treatment of acute duodenal ulcers. J Clin Gastroenterol 1987;9 (Suppl 2):14–18.
Lee FI, Reed PI, Crowe JP, et al: Acute treatment of duodenal ulcers: A multicetre study to compare ranitidine 150 mg twice daily with ranitidine 300 mg once at night. Gut 1986;27:1091–1095.
Kildebo S, Aronsen O, Bernersen B, et al: Cimetidine, 800 mg at night in the treatment of duodenal ulcers. Scand J Gastroenterol 1985;20:1147–1150.
Capurso L, Dal Monte PR, Mazzeo F, et al: Cimetidine, 800 mg at night versus 400 mg twice daily in the treatment of duodenal ulcers. Scand J Gastroenterol 1986:21(Suppl 121):6–10.
Celle G, Savarino V, Mela GS, et al: Once and twice daily doses of H2 antagonists revised using continuous intragastric pH monitoring. Scand J Gastroenterol 1988;23:385–390.
Deakin M, Glenny HP, Ranage JK, et al: Large single daily dose of histamine H2 receptor antagonist for duodenal ulcers. How much and when? A clinical pharmacological study. Gut 1987;28:556–572.
Santana IA, Lanzon-Miller S, Pounder RE: Effect of oral famotidine on 24-hour intragastric acidity. Postgrad Med J 1986;62 (Suppl 2):39–42.
Savarino V, Picciotto A, Magnolia MR, et al: Single bedtime dose of famotidine: Assessment of its antisecretory action by 24-hour intragastric pH monitoring. J Clin Pharmacol 1987;27:790–793.
Malagelada JR, Longstreth GF, Deering TB, et al: Gastric secretion and emptying after ordinary meals in duodenal ulcers. Gastroenterology 1977;73:989–994.
Lam SK, Hui WM, Mathew MT, et al: Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcers. Dig Dis Sci 1989;34:1494–1500.
Sakita T, Fukutomi T: Endoscopic diagnosis. In: Yoshitoshi Y, ed. Ulcers of stomach and duodenum. Tokyo: Nankodo Co. 1971;197–208.
Miyake T, Suzaki T, Oishi M: Correlation of gastric ulcer healing features by endoscopy, stereoscopic microscopy, and histology, and a reclassification of the epithelial regenerative process. Dig Dis Sci 1980;23:8–14.
Merki HS, Witzel L, Walt RP, et al: Day-to-day variation of 24-hor. intragastric acidity. Gastroenterology 1988;84:887–891.
Jones DB, Howden CW, Burget DW, et al: Acid suppression in duodenal ulcers: A metaanalysis to define optimal dosing with antisecretory drugs. Gut 1987;28:1120–1127.
Howden CW, Holt S: Medical treatment of peptic ulcers. Current Opinion in Gastroenterology 1990;6:909–916.
Bauerfeind P, Cilluffo T, Emde C, et al: H2-antagonists are more effective after early evening intake than after late intake (Abstr). Gastroenterology 1986;90:1340.
Merki HS, Witzel L, Harre K, et al: Single dose treatment with H2-receptor antagonists: Is bedtime administration too late? Gut 1987;28:451–454.
Warzee PC, Coppens JP, Feasse R, et al: Ranitidine single dose 300 mg. Influence of the time of administration on gastric acidity (Abstr). Dig Dis Sci 1988;31 (Suppl):333.
Merki HS, Witzel L, Walt RP, et al: Double blind comparison of the effects of cimetidine, ranitidine, famotidine, and placebo on intragastric acidity in 30 normal volunteers. Gut 1988;29:81–84.
Merki H, Witzel L, Hutlemann W, et al: Early evening ranitidine administration promotes faster duodenal ulcer healing. Am J Gastroenterol 1988;83:362–364.
Pretis GD, Dobrilla G, Ferrari A, et al: Comparison between single morning and bedtime doses of 40 mg famotidine for the treatment of duodenal ulcers. Aliment Pharmacol Therap 1989;3:285–291.
Porro GB, Parente F, Sangaletti O: Inhibition of nocturnal acidity is important but not essential for duodenal ulcer healing. Gut 1990;31:397–400.
McCallum RW, Chremos AN, Kuljian B, et al: MK-208, a novel histamine H2-receptor inhibitor with prolonged antisecretory effects. Dig Dis Sci 1985;30:1139–1144.
Lam SK: Pathogenesis and pathophysiology of duodenal ulcers. Clin Gastroenterol 1984;13:447–471.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okada, M., Arita, M., Iida, M. et al. A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers. Gastroenterol Jpn 27, 179–186 (1992). https://doi.org/10.1007/BF02777720
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02777720